An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study

Trial Profile

An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study

Suspended
Phase of Trial: Phase III

Latest Information Update: 05 May 2016

At a glance

  • Drugs PRO 140 (Primary)
  • Indications HIV-1 infections
  • Focus Expanded access; Therapeutic Use
  • Acronyms CD02_EA
  • Sponsors CytoDyn
  • Most Recent Events

    • 29 Apr 2016 Status changed from planning to suspended.
    • 03 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top